VOLUNTARY ANNOUNCEMENT: SIR-SPHERES Y-90 RESIN MICROSPHERES DOSED THE FIRST HCC PATIENT OF THE U.S. CLINICAL TRIAL

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

China Grand Pharmaceutical and Healthcare Holdings Limited

遠大醫藥健康控股有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 00512)

VOLUNTARY ANNOUNCEMENT

SIR-SPHERES® Y-90 RESIN MICROSPHERES DOSED THE FIRST HCC

PATIENT OF THE U.S. CLINICAL TRIAL

This announcement is made by the board of directors (the "Board") of China Grand Pharmaceutical and Healthcare Holdings Limited (the "Company", together with its subsidiaries, the "Group") on a voluntary basis.

The Board is pleased to announce that the core product SIR-Spheres® Y-90 resin microspheres of Sirtex Medical Pty Ltd ("Sirtex"), an associate company of the Group, has successfully dosed the first patient recently, following the approval by the U.S. Food and Drug Administration ("FDA") to conduct a clinical trial for hepatocellular carcinoma ("HCC").

The SIR-Spheres® Y-90 resin microspheres clinical study, DOORwaY90, is being conducted in the United States to evaluate the safety and efficacy of SIR-Spheres® Y-90 resin microspheres as a first-line treatment for patients with unresectable or inoperable HCC patients in order to obtain approval for the HCC indication in the United States. The study will be conducted at 15 oncology centers led by MD Anderson Cancer Center, and will enroll 100 patients in an open single-arm study. The primary clinical endpoints will be the overall response rate (ORR) and duration of response (DoR). DOORwaY90 will be the first U.S. registration trial to utilize and delineate personalized dosimetry treatment planning and to define actionable post-treatment dosimetric verification for endpoint assessment, so as to provide high-quality supporting data for the use of SIR-Spheres® Y-90 resin microspheres in HCC patients to benefit more HCC patients.

The registration of SIR-Spheres® Y-90 resin microspheres in China is progressing smoothly. In August 2020, the National Medical Products Administration of the PRC (NMPA) approved to file the new drug application for the treatment of colorectal liver metastases based on clinical trial data obtained overseas. The new drug application was accepted in November 2020.

SIR-Spheres® Y-90 resin microspheres is a targeted internal radionuclide product for liver malignant tumors, applying the world's leading interventional technology to inject SIR-Spheres® Y-90 resin microspheres into the blood vessels of liver tumors and release high-energy beta radiation to kill tumor cells. In 2002, this product was approved by the FDA for the treatment of unresectable colorectal cancer liver metastases (mCRC) based on the pivotal research CRI9101 (n=74), and in the same year it was approved by the European Union for the treatment of unresectable advanced liver malignancies.

SIR-Spheres® Y-90 resin microspheres have been dosed to over 100,000 patients in more than 50 countries and regions around the world. With its remarkable clinical

1

efficacy, it was recommended for treatment of hepatic malignant tumors by many authoritative guidelines, including National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO). It is also covered by medical insurance in places such as the United States and Europe. In addition, it is included in the Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2019 edition) and Chinese Guidelines for the Diagnosis and Comprehensive Treatment of Colorectal Cancer Liver Metastasis (2018 edition), delineating clear clinical demands.

Sticking to patients-centered and innovation-driven, the Group will continue to expand its strategic planning in anti-tumor field and increase its investment in the world -class innovative products in the fields of radiopharmaceuticals and precision interventional therapy. Through cooperating with the three global leading anti -tumor pharmaceutical companies, U.S. based OncoSec Medical Incorporated (NASDAQ:ONCS), Australia based Sirtex and Telix Pharmaceuticals Limited (ASX: TLX), the Group will continue to introduce world-class innovative products for different cancer indications in response to unmet clinical needs and enrich product pipeline and improve supply chain, dedicating itself into building world-leading radiopharmaceuticals platform and immunotherapy platform integrating diagnostics and treatment. The Group adopts the strategy of "global expansion and dual-cycle operation", forming a new pattern of domestic and international cycles that synergize with each other. The Group makes full use of its domestic industrial advantages and research and development capabilities, to accelerate commercialization process for innovative products and provide cancer patients with more advanced and diverse treatment options in the world.

Warning

The aforementioned clinical trial are still in progress and the returns from commercialization are subject to various factors. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board

China Grand Pharmaceutical and

Healthcare Holdings Limited

Liu Chengwei

Chairman

Hong Kong, 9 May 2021

As at the date of this announcement, the Board comprises four executive directors, namely, Mr. Liu Chengwei, Mr. Hu Bo, Dr. Shao Yan and Dr. Niu Zhanqi and three independent non- executive directors, namely, Ms. So Tosi Wan, Winnie, Dr. Pei Geng and Mr. Hu Yebi.

* For identification purpose only

2